Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels
2007
A 2006 change in Medicare policy allowed reimbursement for erythropoietin (EPO) in dialysis patients whose most recent hemoglobin exceeded 13 g/dl. We investigated the effects of a change in dosing algorithm implemented in response to this policy, in which EPO dosages were reduced instead of temporarily discontinued for hemoglobin levels ≥13 g/dl. Among 1688 individuals in 18 hemodialysis units, the reduction protocol resulted in more hemoglobin levels ≥13 g/dl ( P P ≤ 0.004), no difference in the proportion of levels P
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
14
Citations
NaN
KQI